Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 9, 2010, Pages 894-899

  Wang, Pei ^a   Bai, Chong ^a   Xu, Quan Yi ^a   Xu, Tian Ying ^a   Su, Ding Feng ^a   Sassard, Jean ^a,b   Miao, Chao Yu ^a,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITÉ LYON 1   (France)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

adipose tissue; dyslipidaemia; Lyon hypertensive rat; visfatin

Indexed keywords

ADIPOCYTOKINE; CHOLESTEROL; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME IMMUNOASSAY; GLUCOSE BLOOD LEVEL; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LYON HYPERTENSIVE RAT; MALE; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RAT STRAIN; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WESTERN BLOTTING;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM DISORDERS; LIPIDS; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; RATS; RATS, MUTANT STRAINS; TRIGLYCERIDES;

EID: 77955984663     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05402.x     Document Type: Article

References (41)

1. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006 444 : 875 880.
2. Bluher M. Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes 2009 117 : 241 250.
3. Bogaert YE, Linas S. The role of obesity in the pathogenesis of hypertension. Nat. Clin. Pract. Nephrol. 2009 5 : 101 111.
4. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005 307 : 426 430.
5. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: Role of nicotinamide mononucleotide. Cardiovasc. Res. 2009 81 : 370 380.
6. Fukuhara A, Matsuda M, Nishizawa M et al. Retraction. Science 2007 318 : 565.
7. Revollo JR, Korner A, Mills KF et al. Nampt/PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007 6 : 363 375.
8. Sun Q, Li L, Li R et al. Overexpression of visfatin/PBEF/Nampt alters whole-body insulin sensitivity and lipid profile in rats. Ann. Med. 2009 41 : 311 320.
9. Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ. The novel adipocytokine visfatin exerts direct cardioprotective effects. J. Cell Mol. Med. 2008 12 : 1395 1403.
10. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 2008 78 : 356 365.
11. Kim SR, Bae YH, Bae SK et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim. Biophys. Acta 2008 1783 : 886 895.
12. Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium- dependent relaxation in isolated blood vessels. Biochem. Biophys. Res. Commun. 2009 383 : 503 508.
13. Filippatos TD, Derdemezis CS, Gazi IF et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur. J. Clin. Invest. 2008 38 : 71 2.
14. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin. Endocrinol. 2008 69 : 878 884.
15. Dogru T, Sonmez A, Tasci I et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J. Hum. Hypertens. 2007 21 : 173 175.
16. Gilibert S, Bataillard A, Nussberger J, Sassard J, Kwitek AE. Implication of chromosome 13 on hypertension and associated disorders in Lyon hypertensive rats. J. Hypertens. 2009 27 : 1186 1193.
17. Vincent M, Cartier R, Privat P, Benzoni D, Samani NJ, Sassard J. Major cardiovascular risk factors in Lyon hypertensive rats. A correlation analysis in a segregating population. J. Hypertens. 1996 14 : 469 474.
18. Miao CY, Liu KL, Benzoni D, Sassard J. Acute pressure-natriuresis function shows early impairment in Lyon hypertensive rats. J. Hypertens. 2005 23 : 1225 1231.
19. Vincent M, Boussairi EH, Cartier R et al. High blood pressure and metabolic disorders are associated in the Lyon hypertensive rat. J. Hypertens. 1993 11 : 1179 1185.
20. Emonnot L, Cohen R, Lo M. Renal and metabolic disorders depend on the renin-angiotensin system in Lyon hypertensive rats associated with diabetes. Am. J. Hypertens. 2008 21 : 657 662.
21. Miao CY, Xie HH, Zhan LS, Su DF. Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats. J. Hypertens. 2006 24 : 1125 1135.
22. Fukuchi S, Hamaguchi K, Seike M, Himeno K, Sakata T, Yoshimatsu H. Role of fatty acid composition in the development of metabolic disorders in sucrose-induced obese rats. Exp. Biol. Med. 2004 229 : 486 493.
23. Pecoraro N, Reyes F, Gomez F, Bhargava A, Dallman MF. Chronic stress promotes palatable feeding, which reduces signs of stress: Feedforward and feedback effects of chronic stress. Endocrinology 2004 145 : 3754 3762.
24. Chen H, Hansen MJ, Jones JE, Vlahos R, Anderson GP, Morris MJ. Detrimental metabolic effects of combining long-term cigarette smoke exposure and high-fat diet in mice. Am. J. Physiol. Endocrinol. Metab. 2007 293 : E1564 71.
25. da Luz PL, Favarato D, Faria-Neto JR Jr., Lemos P, Chagas AC. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics 2008 63 : 427 432.
26. Xu TY, Chen RH, Wang P, Zhang RY, Ke SF, Miao CY. 4-Phenyl butyric acid does not generally reduce glucose level in diabetic rodent models. Clin. Exp. Pharmacol. Physiol. 2009 37 : 441 446.
27. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006 55 : 2871 2875.
28. Dahl TB, Yndestad A, Skjelland M et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation 2007 115 : 972 980.
29. Zhang YY, Gottardo L, Thompson R et al. A visfatin promoter polymorphism is associated with low-grade inflammation and Type 2 diabetes. Obesity 2006 14 : 2119 2126.
30. Fasshauer M, Bluher M, Stumvoll M, Tonessen P, Faber R, Stepan H. Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. Clin. Endocrinol. 2007 66 : 434 439.
31. Hu W, Wang Z, Wang H, Huang H, Dong M. Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet. Gynecol. Scand. 2008 87 : 413 418.
32. Yilmaz MI, Saglam M, Carrero JJ et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol. Dial. Transplant. 2008 23 : 959 965.
33. Lopez-Bermejo A, de Zegher F, Diaz-Silva M, Vicente MP, Valls C, Ibanez L. Cord serum visfatin at term birth: Maternal smoking unmasks the relation to foetal growth. Clin. Endocrinol. 2008 68 : 77 81.
34. Jongwutiwes T, Lertvikool S, Leelaphiwat S, Rattanasiri S, Jultanmas R, Weerakiet S. Serum visfatin in Asian women with polycystic ovary syndrome. Gynecol. Endocrinol. 2009 25 : 536 542.
35. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and Type 2 diabetes mellitus in Asian Indians. Metabolism 2007 56 : 565 570.
36. Miao CY, Cai GJ, Tao X, Xie HH, Su DF. Greater hypertrophy in right than left ventricles is associated with pulmonary vasculopathy in sinoaortic-denervated Wistar-Kyoto rats. Clin. Exp. Pharmacol. Physiol. 2004 31 : 450 455.
37. Miao CY, Xie HH, Yu H, Chu ZX, Su DF. Ketanserin stabilizes blood pressure in conscious spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2003 30 : 189 193.
38. Brentano F, Schorr O, Ospelt C et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum. 2007 56 : 2829 2839.
39. Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: Involvement in obesity-associated diseases. Clin. Sci. 2008 114 : 275 288.
40. Adya R, Tan BK, Chen J, Randeva HS. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: Its role in MMP-2/9 production and activation. Diabetes Care 2008 31 : 758 760.
41. Rongvaux A, Galli M, Denanglaire S et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J. Immunol. 2008 181 : 4685 4695.